TP53 mutations of HCC patients in western countries have been reported to be correlated with tumor grade, clinical stage and prognosis, suggesting that these mutations are not causative of carcinogenesis, but features acquired during tumor progression [80,81,82]. This evidence concerns the gene TP53 and neoplasm.